Supplementation of Seaweed Extracts to the Diet Reduces Symptoms of Alzheimer's Disease in the APPswePS1ΔE9 Mouse Model.

Abstract

We previously demonstrated that diet supplementation with seaweed() prevented AD-related pathology in a mouse model of Alzheimer's Disease (AD). Here, we tested a lipid extract of seaweed() and a supercritical fluid (SCF) extract ofthat is free of excess inorganic arsenic. Diet supplementation withextract prevented cognitive deterioration in APPswePS1ΔE9 mice. Similar trends were observed for theSCF extract. The cerebral amyloid-β plaque load remained unaffected. However, IHC analysis revealed that both extracts lowered glial markers in the brains of APPswePS1ΔE9 mice. While cerebellar cholesterol concentrations remained unaffected, both extracts increased desmosterol, an endogenous LXR agonist with anti-inflammatory properties. Both extracts increased cholesterol efflux, and particularly,extract decreased the production of pro-inflammatory cytokines in LPS-stimulated THP-1-derived macrophages. Additionally, our findings suggest a reduction of AD-associated phosphorylated tau and promotion of early oligodendrocyte differentiation by. RNA sequencing on the hippocampus of one-week-treated APPswePS1ΔE9 mice revealed effects ofon, amongst others, acetylcholine and synaptogenesis signaling pathways. In conclusion, extracts ofandshow potential to reduce AD-related pathology in APPswePS1ΔE9 mice. Increasing desmosterol concentrations may contribute to these effects by dampening neuroinflammation.